AstraZeneca receives FDA approvable letter for Seroquel tablets in treatment of mania

ASTRAZENECA RECEIVES FDA APPROVABLE LETTER FOR SEROQUELTM (QUETIAPINE FUMARATE) TABLETS IN TREATMENT OF MANIA AstraZeneca today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) in response to its Supplemental New Drug Applications (sNDAs) for the use of SEROQUEL as both an adjunct and monotherapy for the treatment of manic episodes associated with bipolar disorder. The company is working closely with the FDA to supply information and to finalize labelling. Media Enquiries: Chris Major, +44 (0) 207 304 5028 Investor Enquiries: Mina Blair-Robinson, +44 (0) 207 304 5084 Jonathan Hunt, +44 (0) 207 304 5087 ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download:

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: